Last $2.47 USD
Change Today -0.08 / -3.14%
Volume 356.7K
CYTR On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:00 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$2.47
Previous Close
$2.55
Day High
$2.50
Day Low
$2.41
52 Week High
01/30/14 - $8.35
52 Week Low
12/16/14 - $2.08
Market Cap
137.7M
Average Volume 10 Days
834.3K
EPS TTM
$-1.16
Shares Outstanding
55.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate includes aldoxorubicin that has completed Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi’s sarcoma. It also develops aldoxorubicin, which is in Phase Ib/II clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and is in Phase IIb pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition, the company has evaluated a drug candidate bafetinib, in the ENABLE Phase II clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

cytrx corp (CYTR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $500.0K
Senior Vice President of Drug Development
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

cytrx corp (CYTR) Key Developments

CytRx Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:55 AM

CytRx Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:55 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: David J. Haen, Vice President of Business Development and Investor Relations, Steven A. Kriegsman, Chairman, Chief Executive Officer and President.

CytRx Corporation Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials

CytRx Corporation announced that the Company has received notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted. The FDA has indicated that the partial clinical hold is due to the reported death of a patient with advanced-stage cancer who did not qualify to participate in any of the ongoing aldoxorubicin clinical trials, but had received aldoxorubicin under the Company's expanded access program. At the FDA's request, the Company will amend all aldoxorubicin study protocols to include an appropriate inclusion/exclusion criteria, an additional patient screening assessment and an evaluation of serum electrolytes prior to aldoxorubicin administration. CytRx is working diligently in collaboration with the FDA to seek the release of the clinical hold and resume enrollment in its clinical studies as expeditiously as possible. CytRx currently believes that the partial hold issue will be expeditiously resolved and that enrollment rates and timelines for its ongoing trials will remain materially unchanged. The Company currently expects to announce preliminary results from the ongoing Phase 2 clinical trial of aldoxorubicin in Kaposi's Sarcoma in the second quarter of 2015 and preliminary results from the ongoing Phase 2 clinical trial of aldoxorubicin in glioblastoma multiforme in the first half of 2015. CytRx remains committed to completing enrollment of its ongoing pivotal global Phase 3 trial in second-line soft tissue sarcoma by the end of 2015.

CytRx Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

CytRx Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss before other loss of $13,050,811 against $6,001,084 a year ago. Net loss was $5,625,248 against $9,980,005 a year ago. Basic and diluted net loss per share $0.10 against $0.33 a year ago. For the nine months, the company reported loss before other loss of $36,507,983 against $17,404,342 a year ago. Net loss was $16,680,203 against $20,267,256 a year ago. Basic and diluted net loss per share $0.31 against $0.67 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $2.47 USD -0.08

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,420.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 521.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.